Skip to main content
main-content

Zeitschrift

Cardiovascular Drugs and Therapy

Cardiovascular Drugs and Therapy OnlineFirst articles

28.07.2021 | Original Article

Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells

Nitroglycerin (NTG), a nitric oxide (NO)-releasing vasodilator, is widely used in the clinical treatment of angina pectoris, congestive heart failure, and myocardial infarction [ 1 ]. However, long-term therapy with NTG is frequently associated …

28.07.2021 | Review Article

The Function and Regulation of Platelet P2Y12 Receptor

In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role …

26.07.2021 | Original Article

Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-α, IL-1β, iNOS, and Osteogenic Runx2

Vascular calcification (VC) is a pathogenic status of vessel wall mineralization. Aging and many disease conditions, including diabetes mellitus, atherosclerosis, and chronic kidney disease (CKD), are associated with VC [ 1 ].

19.07.2021 | Original Article

Morphine Prevents Ischemia/Reperfusion-Induced Myocardial Mitochondrial Damage by Activating δ-opioid Receptor/EGFR/ROS Pathway

Acute myocardial infarction (AMI) affects millions of people each year, and the incidence is increasing as the population ages. Although reperfusion of the ischemic heart is an effective way to cure AMI, it may cause irreversible damage to the …

17.07.2021 | Invited Review Article

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic …

Aktuelle Ausgaben

Über diese Zeitschrift

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

Five Reasons to Publish Your Article in Cardiovascular Drugs and Therapy:

· High usage: Articles frequently downloaded from month to month

· Wide distribution: Institutions worldwide having full text access

· Efficient handling: 18 days between submission and first decision

· Fast publication: 17 days between acceptance and online publication

· International readership: North America, Asia, Europe, Middle East and South America

Weitere Informationen

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise